PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Scheibenbogen, C.* ; Bellmann-Strobl, J.T.* ; Heindrich, C.* ; Wittke, K.* ; Stein, E.* ; Franke, C.* ; Prüss, H.* ; Preßler, H.* ; Machule, M.L.* ; Audebert, H.* ; Finke, C.* ; Zimmermann, H.G.* ; Sawitzki, B.* ; Meisel, C.* ; Toelle, M.* ; Krueger, A.* ; Aschenbrenner, A.C.* ; Schultze, J.L.* ; Beyer, M.D.* ; Ralser, M.* ; Mülleder, M.* ; Sander, L.E.* ; Konietschke, F.* ; Paul, F.* ; Stojanov, S.* ; Bruckert, L.* ; Hedderich, D.M.* ; Knolle, F.* ; Riemekasten, G.* ; Vehreschild, M.J.G.T.* ; Cornely, O.A.* ; Behrends, U. ; Burock, S.*

Fighting Post-COVID and ME/CFS – development of curative therapies.

Front. Med. 10:1194754 (2023)
Postprint DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
The sequela of COVID-19 include a broad spectrum of symptoms that fall under the umbrella term post-COVID-19 condition or syndrome (PCS). Immune dysregulation, autoimmunity, endothelial dysfunction, viral persistence, and viral reactivation have been identified as potential mechanisms. However, there is heterogeneity in expression of biomarkers, and it is unknown yet whether these distinguish different clinical subgroups of PCS. There is an overlap of symptoms and pathomechanisms of PCS with postinfectious myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). No curative therapies are available for ME/CFS or PCS. The mechanisms identified so far provide targets for therapeutic interventions. To accelerate the development of therapies, we propose evaluating drugs targeting different mechanisms in clinical trial networks using harmonized diagnostic and outcome criteria and subgrouping patients based on a thorough clinical profiling including a comprehensive diagnostic and biomarker phenotyping.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
3.900
0.000
8
4
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Autoantibodies ; Clinical Trials ; Covid-19 ; Endothelial Dysfunction ; Inflammation ; Me/cfs ; Post-covid; Encephalomyelitis/chronic Fatigue Syndrome; Disease Severity; Symptoms
Language english
Publication Year 2023
HGF-reported in Year 2023
ISSN (print) / ISBN 2296-858X
e-ISSN 2296-858X
Journal Frontiers in Medicine
Quellenangaben Volume: 10, Issue: , Pages: , Article Number: 1194754 Supplement: ,
Publisher Frontiers
Publishing Place Lausanne
Reviewing status Peer reviewed
Institute(s) Research Unit Gene Vector (AGV)
POF-Topic(s) 30203 - Molecular Targets and Therapies
Research field(s) Immune Response and Infection
PSP Element(s) G-501500-001
Grants r Bildung und Forschung (German Ministry of Education and Research)
Bundesministerium fuuml
DOI 10.3389/fmed.2023.1194754
WOS ID 001016151200001
Scopus ID 85164388992
PubMed ID 37396922
Erfassungsdatum 2023-10-18
[➜Report correction]